Immunohistochemical localization of tumor markers in epithelial ovarian cancer

Casper, Scott E.; Nagell, J.R. van; Powell, D.F.; Dubilier, Louis D.; Donaldson, Elvis S.; Hanson, M.; Pavlik, Edward J.

doi:10.1016/0002-9378(84)90188-1

Cited by 34 publications

(5 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to the past literature, more than 38% of epithelial ovarian carcinoma secrete detectable amounts of AFP (Bose and Mukherjea, 1993), and 6.5% show histochemical evidence of AFP secretion in individual cells (Casper et al, 1984). Therefore, it is important not only to determine each different histological type, but also to distinguish immunohistochemically between the YST component and the endometrioid component.…”

Section: Discussionmentioning

confidence: 99%

A case of ovarian yolk sac tumor associated with endometrioid adenocarcinoma

Koi

Kurita

Kagami

et al. 2014

Gynecologic Oncology Case Reports

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

A case of ovarian yolk sac tumor associated with endometrioid adenocarcinoma

Koi

Kurita

Kagami

et al. 2014

Gynecologic Oncology Case Reports

View full text Add to dashboard Cite

“…HE4 protein is expressed in the reproductive tract, in the upper airways, is detected in the sera of patients, but it's not elevated in benign gynecological diseases [65]. In OC several IHC studies agree in indicating a prevalent expression of the CEA antigen in the ovarian mucinous histotype [66][67][68]. CEA results to be detectable in less that 20% of serous malignancies and in none of the specimens of normal ovaries [66].…”

Section: Tumor Associated Antigensmentioning

confidence: 94%

Immunology of Gynecologic Neoplasms: Analysis of the Prognostic Significance of the Immune Status

Bellati¹,

Visconti

Napoletano³

et al. 2009

CCDT

View full text Add to dashboard Cite

Gynecologic Oncology has changed in the last few decades. An increasing proportion of patients is benefiting from long term survival although patients diagnosed with advanced disease suffer from a poor prognosis. Unfortunately, several recent studies are confirming that changing the combinations of "traditional" cytotoxic drugs is unlikely to obtain a real breakthrough in survival rates. Furthermore, there is discouraging data regarding consolidation therapies. It is, therefore, necessary to identify new target therapies with a minimal impact on quality of life. It is likely that new breakthroughs are only going to be achieved when changes in therapies are tailored to the entire natural history of the disease and on specific patient characteristic's. Since the discovery that tumor infiltrating lymphocytes represent an independent prognostic factor in ovarian cancer patients, several researchers have dedicated their attention to cancer immune response in order to identify prognostic factors and immunological targets. Analyses on immunophenotype at diagnosis and throughout the entire course of treatment are currently ongoing and are giving the new diagnostic, prognostic and therapeutic tools to the physicians. Furthermore new antigens and new vaccination strategies are being investigated. Encouraging data on selected patient populations have been observed recently. The objective of the present review is to define the immunology of women affected by gynecological malignancies and describe new immunological targets for prognostic and therapeutic use.

show abstract

“…It has been reported that carcinomas of somatic origin are occasionally associated with elevated serum AFP and positive staining for AFP [9,10]. Abe.…”

Section: Discussionmentioning

confidence: 99%

Alpha-fetoprotein (AFP)-producing epithelial ovarian carcinoma (EOC): a retrospective study of 27 cases

Chen

Wang

Cao

et al. 2021

Arch Gynecol Obstet

View full text Add to dashboard Cite

Objective The aim of the study was to investigate the relative risk factors associated with the prognosis and effective treatments of alpha-fetoprotein (AFP)-producing epithelial ovarian carcinoma (EOC). Method We presented three cases of AFP-producing EOC and performed a brief review to summarize the clinicopathological features and prognostic factors of 24 cases that have been previously reported. We evaluated the correlations among prognostic and clinical parameters, such as stage, pathology and chemotherapy regimens. In addition, a retrospective review of these 27 cases was conducted, and survival curves were estimated using the Kaplan–Meier method. Results The patients were aged between 23 and 77 years. The median overall survival was 10 months, and ten (37.04%) patients died within 18 months. We compared the overall mean survival times of all patients in different stages, and the results suggest that the postoperative pathological staging is hardly correlated with prognosis ( P = 0.76). There was a correlation between pathology and prognosis ( P = 0.0018). The mean survival time was longer for patients who had undergone chemotherapy than for those without chemotherapy (14.88 vs 0.65 months) ( P < 0.0001). Moreover, although patients had a good response to the regimens for PEB and TC ( P = 0.004), there was no significant difference between PEB and TC ( P = 0.386). Conclusions AFP-producing EOC is uncommon and regarded as an extremely malignant type of tumor. Patients with chemotherapy may have a longer survival time; additionally, PEB and TC may be an optimal selection for this kind of tumor. Further large-scale studies are needed to confirm our findings.

show abstract

Immunohistochemical localization of tumor markers in epithelial ovarian cancer

Cited by 34 publications

References 12 publications

A case of ovarian yolk sac tumor associated with endometrioid adenocarcinoma

A case of ovarian yolk sac tumor associated with endometrioid adenocarcinoma

Immunology of Gynecologic Neoplasms: Analysis of the Prognostic Significance of the Immune Status

Alpha-fetoprotein (AFP)-producing epithelial ovarian carcinoma (EOC): a retrospective study of 27 cases

Contact Info

Product

Resources

About